Healwell AI's xAI Windfall Could Fund a Pivot That's Already Gaining Traction

Healwell AI's indirect stake in Elon Musk's xAI could yield over 15M CAD, offsetting a weak quarter as it pivots from clinical ops to a subscription-based AI platform.

The Canadian healthcare AI company Healwell AI finds itself in an unusual position: its core business is undergoing a radical transformation, while an indirect stake in Elon Musk's xAI — now folded into SpaceX following a February 2026 merger — could provide a financial cushion worth more than 15 million Canadian dollars. That potential liquidity event, flagged by Stifel analyst Justin Keywood, arrives as the company prepares to report what management itself has called the weakest quarter of the year.

The xAI Factor

Healwell originally invested 2 million US dollars in a vehicle holding an xAI stake. With xAI's absorption into SpaceX, that position is now effectively tied to the rocket-and-satellite giant. The company is exploring monetization options, though no formal steps have been announced. Keywood estimates a sale could generate over 15 million CAD, a sum that would meaningfully reduce debt and strengthen the balance sheet.

The timing is fortuitous. Healwell is shedding its clinical operations to become a pure-play AI software company built on recurring subscription revenue. The sale of HEAL Access Canada to AI Maverick Intel, signed via a letter of intent in late March, is expected to close with a binding agreement by May 29. The consideration includes 20 million exchangeable shares and a secured vendor note worth roughly 5 million CAD. Separately, the divestiture of Polyclinic Family Medicine and Specialty Group to WELL Health Clinic Network brought in about 9.7 million CAD in the fourth quarter alone.

Revenue Surge, Accounting Loss

The numbers for fiscal 2025 tell a story of rapid growth and persistent red ink. Revenue from continuing operations hit approximately 103.8 million CAD, a 427% jump from the prior year, fueled largely by acquisitions. For the first time, Healwell posted a full-year adjusted EBITDA profit of 2.3 million CAD. Yet under IFRS accounting, the net loss stood at 39.1 million CAD — a gap between management's preferred metrics and standard reporting that continues to draw scrutiny from institutional investors.

The stock reflects this tension. Trading at roughly 0.61 euros, it sits 41% below its 52-week high, though it has recovered significantly from a February trough of 0.37 euros. Keywood notes that Healwell is valued at 2.4 times revenue, while comparable life-sciences technology companies trade at an average of 2.8 times. The consensus analyst price target of 2.68 CAD implies substantial upside, even as the relative strength index of 24.6 signals technically oversold conditions.

The Amadeus AI Bet

The commercial centerpiece of the new strategy is Amadeus AI, a platform that consolidates the former Khure and Pentavere products under a unified AI engine. It draws on data from more than 150 million patient records. A North American launch is slated for the first half of 2026, with international expansion planned for year-end.

For the full year, management targets roughly 50% organic growth in AI revenue and an adjusted EBITDA margin of about 10%. The integration of Orion Health and the appointment of Brad Porter to the board are intended to support those goals. Keywood expects Healwell to reach free-cash-flow neutrality by the fourth quarter of 2026, assuming organic contract wins and the xAI monetization materialize.

What to Watch

The first real test comes on May 19, when Healwell reports first-quarter 2026 results. That report will offer the earliest glimpse of whether Amadeus AI is gaining traction and whether the xAI stake could provide a near-term catalyst.

Shareholders will also want to mark June 25, the date of the annual general meeting, where management is expected to provide updates on expansion in the Middle East and adoption among North American enterprise clients — two growth vectors that remain largely unquantified. The record date for voting shareholders is May 15.